Tamoxifen

Tamoxifen is a nonsteroidal compound of the triphenylethylene class and the prototype of the drugs known as selective estrogen receptor modulators ^[2]. It was first synthesized in 1962 at the British company ICI as part of a program to develop a contraceptive, but although it blocked estrogen in some tissues it stimulated rather than suppressed ovulation in women and could not fill that role ^[1]. The project was nearly abandoned before the compound was redirected toward breast cancer, an application in which it proved highly successful and eventually became a best-selling medicine ^[1].

Tamoxifen's principal use is in breast cancers that carry estrogen receptors, where it is given both after primary treatment to reduce recurrence and as a preventive in women at elevated risk; it was the first drug shown to prevent a cancer, helping to establish the concept of chemoprevention ^[1]. It is also used in men with breast cancer and has further applications in conditions such as gynecomastia and certain causes of infertility ^[2]. Standard courses of therapy typically extend over several years ^[1].

The drug is in effect a prodrug that the liver converts into more active substances, chiefly endoxifen and afimoxifene, which bind the estrogen receptor far more strongly than tamoxifen itself ^[3]. Because the enzyme CYP2D6 drives this activation, genetic differences in that enzyme, and drugs that inhibit it such as some antidepressants, can influence how well tamoxifen works ^[3]. Tamoxifen has been available since the 1970s, became generic around the start of the 2000s, and is a prescription-only medicine; its recognized risks include a raised chance of uterine cancer and of blood clots, reflecting its estrogen-like activity in some tissues ^[1][3].

Tamoxifen is a selective estrogen receptor modulator whose common effects include hot flashes, menstrual changes, and mood changes. Serious risks include venous thromboembolism (deep vein thrombosis and pulmonary embolism), stroke, and, from its estrogenic effect on the uterus, endometrial hyperplasia and uterine cancer. It can also cause cataracts and liver effects, is teratogenic and must not be used in pregnancy, and interacts with CYP2D6 inhibitors such as certain antidepressants.

Tamoxifen is a selective estrogen receptor modulator whose efficacy depends critically on conversion to its active metabolite endoxifen by CYP2D6. Strong inhibitors of CYP2D6, particularly certain antidepressants like paroxetine and fluoxetine, reduce endoxifen formation and may compromise breast cancer recurrence prevention ^[22]. This is a pharmacokinetic interaction where the antidepressant changes tamoxifen's metabolic pathway.

The interaction is clinically significant enough that some providers preferentially select antidepressants with minimal CYP2D6 inhibition when treating tamoxifen patients ^[23]. The effect is bidirectional in terms of clinical relevance; patients with naturally impaired CYP2D6 metabolism (due to genetic polymorphism) show reduced tamoxifen efficacy unless dosage is escalated ^[23]. Few data exist on tamoxifen with non-CYP2D6 inhibiting medications, and many common drug combinations remain unexamined.

Checking a whole stack? Run it through interactions + stacks.

Tamoxifen originated in the early 1960s at the British pharmaceutical company ICI (Imperial Chemical Industries, later Zeneca and then AstraZeneca), where it was synthesized as compound ICI 46,474 during a research program aimed at developing a contraceptive. It failed as a contraceptive, but the chemist Dorothy Bishop and the pharmacologist Arthur Walpole, together with later work led by V. Craig Jordan, recognized its antiestrogenic potential in breast tissue, and Jordan's studies in the 1970s established the scientific rationale for its use against hormone-sensitive breast cancer.

The drug was first approved in the United Kingdom in 1973 and by the US FDA in 1977, and over subsequent decades it became a cornerstone of adjuvant therapy for estrogen-receptor-positive disease. Landmark prevention trials in the 1990s, including the NSABP P-1 study, extended its role to lowering breast-cancer risk in high-risk women. Tamoxifen is now listed on the World Health Organization's Model List of Essential Medicines and is often cited as one of the most influential drugs in oncology history.

Tamoxifen enjoys a well-earned reputation as one of the most consequential cancer medicines ever developed, credited with preventing hundreds of thousands of breast-cancer deaths worldwide. It was among the first targeted therapies, exploiting the biology of the estrogen receptor decades before the phrase targeted therapy became common, and it remains a reference point for the concept of the selective estrogen receptor modulator.

Its long track record, low cost, and oral once-daily dosing make it accessible across the globe, and its benefit in both treatment and risk reduction is supported by some of the largest and longest-running trials in oncology. Research continues into how CYP2D6 genotype shapes the formation of its active metabolite endoxifen, an area of genuine scientific interest. Honesty requires noting its tissue-selective nature also brings a small increase in endometrial-cancer and thromboembolic risk, which is why it is used under medical supervision.